Zoetis Inc. $ZTS Shares Sold by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 15.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 83,034 shares of the company’s stock after selling 15,626 shares during the period. Cary Street Partners Financial LLC’s holdings in Zoetis were worth $10,447,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Allstate Corp lifted its position in Zoetis by 106.1% during the 4th quarter. Allstate Corp now owns 32,227 shares of the company’s stock worth $4,055,000 after acquiring an additional 16,592 shares in the last quarter. Fisher Asset Management LLC lifted its position in Zoetis by 25.2% during the 4th quarter. Fisher Asset Management LLC now owns 2,975 shares of the company’s stock worth $374,000 after acquiring an additional 599 shares in the last quarter. Clearstead Trust LLC lifted its position in Zoetis by 541.7% during the 4th quarter. Clearstead Trust LLC now owns 3,497 shares of the company’s stock worth $440,000 after acquiring an additional 2,952 shares in the last quarter. Legal & General Group Plc lifted its position in Zoetis by 4.1% during the 4th quarter. Legal & General Group Plc now owns 3,554,498 shares of the company’s stock worth $447,227,000 after acquiring an additional 138,654 shares in the last quarter. Finally, Morningstar Investment Management LLC acquired a new position in Zoetis during the 4th quarter worth approximately $6,264,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.

Zoetis Stock Performance

Shares of ZTS opened at $81.26 on Tuesday. The business’s 50 day moving average is $107.43 and its two-hundred day moving average is $118.17. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $172.23. The firm has a market cap of $34.06 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 1.33 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company earned $1.48 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. JPMorgan Chase & Co. cut their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Stifel Nicolaus cut their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Friday. UBS Group cut their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Finally, Bank of America upped their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.